Calliditas Therapeutics: Interim Report Q1, 2023 ...Middle East

PR Newswire - News
STOCKHOLM, May 16, 2023 /PRNewswire/ -- Strong eGFR Data from Positive NefIgArd Phase 3 Trial Readout "In March we announced that the global NefIgArd Phase 3 trial successfully met its primary endpoint, estimated glomerular filtration rate (eGFR), with a p value < 0.0001. Achieving this...

Hence then, the article about calliditas therapeutics interim report q1 2023 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Calliditas Therapeutics: Interim Report Q1, 2023 )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News